Tu uhevaha J Kaitu u-Lino

List of Publications by Year in Descending Order

106 papers	1,946 citations	25 h-index	39 g-index
107 ext. papers	2,461 ext. citations	4.2 avg, IF	4.8 L-index

#	Paper	IF	Citations
106	Circulating SPINT1 in the second trimester is reduced among pregnancies that ends in low birthweight neonates: cohort study of 2006 pregnancies.. *American Journal of Obstetrics & Gynecology MFM*, **2022**, 100618	7.4	0
105	PSG7 and 9 (Pregnancy-Specific ß1 Glycoproteins 7 and 9): Novel Biomarkers for Preeclampsia.. *Journal of the American Heart Association*, **2022**, e024536	6	1
104	Circulating Activin A is elevated at 36 weeks gestation preceding a diagnosis of preeclampsia. *Pregnancy Hypertension*, **2021**, 27, 23-26	2.6	0
103	Clinical tools and biomarkers to predict preeclampsia.. *EBioMedicine*, **2021**, 75, 103780	8.8	6
102	NR4A2 expression is not altered in placentas from cases of growth restriction or preeclampsia, but is reduced in hypoxic cytotrophoblast. *Scientific Reports*, **2021**, 11, 20670	4.9	
101	A disintegrin and metalloproteinase 12 (ADAM12) is reduced at 36 weeks gestation in pregnancies destined to deliver small for gestational age infants. *Placenta*, **2021**, 117, 1-4	3.4	1
100	DAAM2 is elevated in the circulation and placenta in pregnancies complicated by fetal growth restriction and is regulated by hypoxia. *Scientific Reports*, **2021**, 11, 5540	4.9	2
99	Maternal circulating SPINT1 is reduced in small-for-gestational age pregnancies at 26 weeks: Growing up in Singapore towards health outcomes (GUSTO) cohort study. *Placenta*, **2021**, 110, 24-28	3.4	4
98	Elevated Circulating and Placental SPINT2 Is Associated with Placental Dysfunction. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	3
97	Nanoparticles in pregnancy: the next frontier in reproductive therapeutics. *Human Reproduction Update*, **2021**, 27, 280-304	15.8	10
96	Circulating Tissue Factor Pathway Inhibitor (TFPI) is increased preceding preeclampsia diagnosis and in established preeclampsia. *Placenta*, **2021**, 105, 32-40	3.4	5
95	Pre-Clinical Investigation of Cardioprotective Beta-Blockers as a Therapeutic Strategy for Preeclampsia. *Journal of Clinical Medicine*, **2021**, 10,	5.1	1
94	Circulating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondria. *Scientific Reports*, **2021**, 11, 16595	4.9	1
93	LOX-1 expression is reduced in placenta from pregnancies complicated by preeclampsia and in hypoxic cytotrophoblast. *Pregnancy Hypertension*, **2021**, 25, 255-261	2.6	1
92	Circulating Growth Differentiation Factor 15 Is Increased Preceding Preeclampsia Diagnosis: Implications as a Disease Biomarker. *Journal of the American Heart Association*, **2021**, 10, e020302	6	4
91	Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial. *BMJ, The*, **2021**, 374, n2103	5.9	8
90	Analysis of mitochondrial regulatory transcripts in publicly available datasets with validation in placentae from pre-term, post-term and fetal growth restriction pregnancies. *Placenta*, **2021**, 112, 162-171	3.4	2

89	Placental growth factor is negatively regulated by epidermal growth factor receptor (EGFR) signaling. *Placenta*, **2021**, 114, 22-28	3.4	0
88	Measuring circulating miRNAs in early pregnancy could identify fetusesSdestined to undergrow and be at increased risk of stillbirth. *EBioMedicine*, **2021**, 63, 103172	8.8	
87	Circulating SPINT1 is a biomarker of pregnancies with poor placental function and fetal growth restriction. *Nature Communications*, **2020**, 11, 2411	17.4	18
86	Aurora kinase mRNA expression is reduced with increasing gestational age and in severe early onset fetal growth restriction. *Placenta*, **2020**, 95, 53-61	3.4	2
85	Circulating Delta-like homolog 1 (DLK1) at 36 weeks is correlated with birthweight and is of placental origin. *Placenta*, **2020**, 91, 24-30	3.4	6
84	Combining metformin and sulfasalazine additively reduces the secretion of antiangiogenic factors from the placenta: Implications for the treatment of preeclampsia. *Placenta*, **2020**, 95, 78-83	3.4	7
83	Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction. *Pregnancy Hypertension*, **2020**, 20, 83-91	2.6	15
82	Circulating mRNAs are differentially expressed in pregnancies with severe placental insufficiency and at high risk of stillbirth. *BMC Medicine*, **2020**, 18, 145	11.4	13
81	Novel approaches to combat preeclampsia: from new drugs to innovative delivery. *Placenta*, **2020**, 102, 10-16	3.4	10
80	MicroRNAs 363 and 149 are differentially expressed in the maternal circulation preceding a diagnosis of preeclampsia. *Scientific Reports*, **2020**, 10, 18077	4.9	6
79	Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia. *Pregnancy Hypertension*, **2020**, 22, 86-92	2.6	5
78	Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia. *American Journal of Obstetrics and Gynecology*, **2020**,	6.4	19
77	Screening circulating proteins to identify biomarkers of fetal macrosomia. *BMC Research Notes*, **2019**, 12, 587	2.3	
76	Sulfasalazine decreases soluble fms-like tyrosine kinase-1 secretion potentially via inhibition of upstream placental epidermal growth factor receptor signalling. *Placenta*, **2019**, 87, 53-57	3.4	4
75	Death associated protein kinase 1 (DAPK-1) is increased in preeclampsia. *Placenta*, **2019**, 88, 1-7	3.4	6
74	Circulating GATA2 mRNA is decreased among women destined to develop preeclampsia and may be of endothelial origin. *Scientific Reports*, **2019**, 9, 235	4.9	4
73	A double blind, randomised, placebo-controlled trial to evaluate the efficacy of metformin to treat preterm pre-eclampsia (PI2 Trial): study protocol. *BMJ Open*, **2019**, 9, e025809	3	25
72	Sulfasalazine reduces placental secretion of antiangiogenic factors, up-regulates the secretion of placental growth factor and rescues endothelial dysfunction. *EBioMedicine*, **2019**, 41, 636-648	8.8	22

71	Circulating adrenomedullin mRNA is decreased in women destined to develop term preeclampsia. *Pregnancy Hypertension*, **2019**, 16, 16-25	2.6	6
70	Blood-based biomarkers in the maternal circulation associated with fetal growth restriction. *Prenatal Diagnosis*, **2019**, 39, 947-957	3.2	6
69	The untapped potential of placenta-enriched molecules for diagnostic and therapeutic development. *Placenta*, **2019**, 84, 28-31	3.4	14
68	EGFR (Epidermal Growth Factor Receptor) Signaling and the Mitochondria Regulate sFlt-1 (Soluble FMS-Like Tyrosine Kinase-1) Secretion. *Hypertension*, **2019**, 73, 659-670	8.5	27
67	Vinorelbine Potently Induces Placental Cell Death, Does Not Harm Fertility and is a Potential Treatment for Ectopic Pregnancy. *EBioMedicine*, **2018**, 29, 166-176	8.8	3
66	Effect of sildenafil citrate on circulating levels of sFlt-1 in preeclampsia. *Pregnancy Hypertension*, **2018**, 13, 1-6	2.6	5
65	Melatonin enhances antioxidant molecules in the placenta, reduces secretion of soluble fms-like tyrosine kinase 1 (sFLT) from primary trophoblast but does not rescue endothelial dysfunction: An evaluation of its potential to treat preeclampsia. *PLoS ONE*, **2018**, 13, e0187082	3.7	23
64	Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction - implications for treating preeclampsia. *PLoS ONE*, **2018**, 13, e0188845	3.7	25
63	Disulfiram inhibits placental soluble FMS-like tyrosine kinase-1 and soluble endoglin secretion independent of the proteasome. *Pregnancy Hypertension*, **2018**, 14, 125-130	2.6	0
62	EGFL7 gene expression is regulated by hypoxia in trophoblast and altered in the plasma of patients with early preeclampsia. *Pregnancy Hypertension*, **2018**, 14, 115-120	2.6	4
61	Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study. *BMC Pregnancy and Childbirth*, **2018**, 18, 354	3.2	15
60	ELABELA/APELA Levels Are Not Decreased in the Maternal Circulation or Placenta among Women with Preeclampsia. *American Journal of Pathology*, **2018**, 188, 1749-1753	5.8	26
59	Variable effect of maternal oral glucose load on circulating cell-free placental mRNAs. *Journal of Maternal-Fetal and Neonatal Medicine*, **2017**, 30, 501-503	2	0
58	Maternal plasma concentrations of the placental specific sFLT-1 variant, sFLT-1 e15a, in fetal growth restriction and preeclampsia. *Journal of Maternal-Fetal and Neonatal Medicine*, **2017**, 30, 635-639	2	11
57	Key players of the necroptosis pathway RIPK1 and SIRT2 are altered in placenta from preeclampsia and fetal growth restriction. *Placenta*, **2017**, 51, 1-9	3.4	11
56	Proton Pump Inhibitors Decrease Soluble fms-Like Tyrosine Kinase-1 and Soluble Endoglin Secretion, Decrease Hypertension, and Rescue Endothelial Dysfunction. *Hypertension*, **2017**, 69, 457-468	8.5	84
55	Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction - implications as a preeclampsia treatment. *Scientific Reports*, **2017**, 7, 1819	4.9	39
54	Epidermal Growth Factor Rescues Endothelial Dysfunction in Primary Human Tissues In Vitro. *Reproductive Sciences*, **2017**, 24, 1245-1252	3	11

53	Activating Transcription Factor 3 Is Reduced in Preeclamptic Placentas and Negatively Regulates sFlt-1 (Soluble fms-Like Tyrosine Kinase 1), Soluble Endoglin, and Proinflammatory Cytokines in Placenta. *Hypertension*, **2017**, 70, 1014-1024	8.5	16
52	sFlt-1 and soluble endoglin concentrations in serum vs plasma in preterm preeclampsia: Are they interchangeable for biomarker studies?. *Pregnancy Hypertension*, **2017**, 10, 18-21	2.6	6
51	Nuclear factor of activated T-cells (NFAT) regulates soluble fms-like tyrosine kinase-1 secretion (sFlt-1) from human placenta. *Placenta*, **2016**, 48, 110-118	3.4	7
50	Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta. *BMC Pregnancy and Childbirth*, **2016**, 16, 117	3.2	32
49	Loss of Akt increases soluble endoglin release from endothelial cells but not placenta. *Pregnancy Hypertension*, **2016**, 6, 95-102	2.6	6
48	Jumonji Domain Containing Protein 6 Is Decreased in Human Preeclamptic Placentas and Regulates sFLT-1 Splice Variant Production. *Biology of Reproduction*, **2016**, 94, 59	3.9	14
47	Identifying late-onset fetal growth restriction by measuring circulating placental RNA in the maternal blood at 28 weeksSgestation. *American Journal of Obstetrics and Gynecology*, **2016**, 214, 521.e1-521.e8	6.4	17
46	Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. *American Journal of Obstetrics and Gynecology*, **2016**, 214, 356.e1-356.e15	6.4	121
45	Placental Growth Factor Is Secreted by the Human Endometrium and Has Potential Important Functions during Embryo Development and Implantation. *PLoS ONE*, **2016**, 11, e0163096	3.7	17
44	Steroid sulfatase is increased in the placentas and whole blood of women with early-onset preeclampsia. *Placenta*, **2016**, 48, 72-79	3.4	7
43	A comparison of sample collection methods for quantifying cell-free fetal neurodevelopment transcripts in amniotic fluid. *BMC Research Notes*, **2016**, 9, 335	2.3	2
42	ATF3 is a negative regulator of inflammation in human fetal membranes. *Placenta*, **2016**, 47, 63-72	3.4	12
41	Transcription factors E2F1 and E2F3 are expressed in placenta but do not regulate MMP14. *Placenta*, **2015**, 36, 932-7	3.4	8
40	Human HtrA4 Expression Is Restricted to the Placenta, Is Significantly Up-Regulated in Early-Onset Preeclampsia, and High Levels of HtrA4 Cause Endothelial Dysfunction. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, E936-45	5.6	27
39	Expression of Myostatin in Intrauterine Growth Restriction and Preeclampsia Complicated Pregnancies and Alterations to Cytokine Production by First-Trimester Placental Explants Following Myostatin Treatment. *Reproductive Sciences*, **2015**, 22, 1202-11	3	3
38	Effects of Pravastatin on Human Placenta, Endothelium, and Women With Severe Preeclampsia. *Hypertension*, **2015**, 66, 687-97; discussion 445	8.5	111
37	Placental-Specific sFLT-1 e15a Protein Is Increased in Preeclampsia, Antagonizes Vascular Endothelial Growth Factor Signaling, and Has Antiangiogenic Activity. *Hypertension*, **2015**, 66, 1251-9	8.5	58
36	Heme Oxygenase-1 Is Not Decreased in Preeclamptic Placenta and Does Not Negatively Regulate Placental Soluble fms-Like Tyrosine Kinase-1 or Soluble Endoglin Secretion. *Hypertension*, **2015**, 66, 1073-81	8.5	24

35	YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia. *Molecular and Cellular Endocrinology*, **2015**, 413, 202-8	4.4	23
34	A wash step at collection of placental biopsies from preeclamptic pregnancies does not adversely affect levels of sFlt-1 or endoglin. *Pregnancy Hypertension*, **2015**, 5, 294-7	2.6	
33	Paternal obesity in a rodent model affects placental gene expression in a sex-specific manner. *Reproduction*, **2015**, 149, 435-44	3.8	42
32	Chorioamnionitis Occurring in Women With Preterm Rupture of the Fetal Membranes Is Associated With a Dynamic Increase in mRNAs Coding Cytokines in the Maternal Circulation. *Reproductive Sciences*, **2015**, 22, 852-9	3	14
31	Sofalcone upregulates the nuclear factor (erythroid-derived 2)-like 2/heme oxygenase-1 pathway, reduces soluble fms-like tyrosine kinase-1, and quenches endothelial dysfunction: potential therapeutic for preeclampsia. *Hypertension*, **2015**, 65, 855-62	8.5	38
30	Placental SEMA3B expression is not altered in severe early onset preeclampsia. *Placenta*, **2014**, 35, 1102-5	3.4	5
29	Stability of absolute copy number of housekeeping genes in preeclamptic and normal placentas, as measured by digital PCR. *Placenta*, **2014**, 35, 1106-9	3.4	16
28	PAPPA2 is increased in severe early onset pre-eclampsia and upregulated with hypoxia. *Reproduction, Fertility and Development*, **2014**, 26, 351-7	1.8	28
27	A bioplex analysis of cytokines and chemokines in first trimester maternal plasma to screen for predictors of miscarriage. *PLoS ONE*, **2014**, 9, e93320	3.7	12
26	Peptides do not prevent cleavage of endoglin to produce soluble endoglin. *Pregnancy Hypertension*, **2014**, 4, 255-8	2.6	
25	Characterization of protocols for primary trophoblast purification, optimized for functional investigation of sFlt-1 and soluble endoglin. *Pregnancy Hypertension*, **2014**, 4, 287-95	2.6	45
24	Measuring thyroid peroxidase antibodies on the day nulliparous women present for management of miscarriage: a descriptive cohort study. *Reproductive Biology and Endocrinology*, **2013**, 11, 40	5	4
23	MT-MMPs in pre-eclamptic placenta: relationship to soluble endoglin production. *Placenta*, **2013**, 34, 168-73	3.4	16
22	Targeted nanoparticle delivery of doxorubicin into placental tissues to treat ectopic pregnancies. *Endocrinology*, **2013**, 154, 911-9	4.8	31
21	Effects of gefitinib, an epidermal growth factor receptor inhibitor, on human placental cell growth. *Obstetrics and Gynecology*, **2013**, 122, 737-744	4.9	17
20	Corin, an enzyme with a putative role in spiral artery remodeling, is up-regulated in late secretory endometrium and first trimester decidua. *Human Reproduction*, **2013**, 28, 1172-80	5.7	23
19	Placental specific mRNA in the maternal circulation are globally dysregulated in pregnancies complicated by fetal growth restriction. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, E429-36	5.6	43
18	Maternal Serum Macrophage Inhibitory Cytokine-1 as a Biomarker for Ectopic Pregnancy in Women with a Pregnancy of Unknown Location. *PLoS ONE*, **2013**, 8, e66339	3.7	4

17	Plasma MIC-1 and PAPP-a levels are decreased among women presenting to an early pregnancy assessment unit, have fetal viability confirmed but later miscarry. *PLoS ONE*, **2013**, 8, e72437	3.7	14
16	Maternal serum interleukin-33 and soluble ST2 across early pregnancy, and their association with miscarriage. *Journal of Reproductive Immunology*, **2012**, 95, 46-9	4.2	19
15	Role of label-retaining cells in estrogen-induced endometrial regeneration. *Reproductive Sciences*, **2012**, 19, 102-14	3	41
14	MMP-14 is expressed in preeclamptic placentas and mediates release of soluble endoglin. *American Journal of Pathology*, **2012**, 180, 888-894	5.8	56
13	MMP-15 is upregulated in preeclampsia, but does not cleave endoglin to produce soluble endoglin. *PLoS ONE*, **2012**, 7, e39864	3.7	14
12	Evaluation of ADAM-12 as a diagnostic biomarker of ectopic pregnancy in women with a pregnancy of unknown location. *PLoS ONE*, **2012**, 7, e41442	3.7	10
11	Identification of label-retaining perivascular cells in a mouse model of endometrial decidualization, breakdown, and repair. *Biology of Reproduction*, **2012**, 86, 184	3.9	25
10	Serum concentrations of soluble Flt-1 are decreased among women with a viable fetus and no symptoms of miscarriage destined for pregnancy loss. *PLoS ONE*, **2012**, 7, e32509	3.7	14
9	Extracellular matrix dynamics in scar-free endometrial repair: perspectives from mouse in vivo and human in vitro studies. *Biology of Reproduction*, **2011**, 85, 511-23	3.9	19
8	Reepithelialization of the uterine surface arises from endometrial glands: evidence from a functional mouse model of breakdown and repair. *Endocrinology*, **2010**, 151, 3386-95	4.8	43
7	A new role for activin in endometrial repair after menses. *Endocrinology*, **2009**, 150, 1904-11	4.8	25
6	Stimulation of epithelial repair is a likely mechanism for the action of mifepristone in reducing duration of bleeding in users of progestogen-only contraceptives. *Reproduction*, **2008**, 136, 267-74	3.8	10
5	Neutrophil depletion retards endometrial repair in a mouse model. *Cell and Tissue Research*, **2007**, 328, 197-206	4.2	69
4	Claudin-11 expression and localisation is regulated by androgens in rat Sertoli cells in vitro. *Reproduction*, **2007**, 133, 1169-79	3.8	117
3	Estrogen is not essential for full endometrial restoration after breakdown: lessons from a mouse model. *Endocrinology*, **2007**, 148, 5105-11	4.8	53
2	The long-term actions of etonogestrel and levonorgestrel on decidualized and non-decidualized endometrium in a mouse model mimic some effects of progestogen-only contraceptives in women. *Reproduction*, **2007**, 133, 309-21	3.8	15
1	Complex expression patterns support potential roles for maternally derived activins in the establishment of pregnancy in mouse. *Reproduction*, **2006**, 132, 799-810	3.8	32